| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ... Nature 486 (7404), 532-536, 2012 | 2111 | 2012 |
| Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution S Misale, F Di Nicolantonio, A Sartore-Bianchi, S Siena, A Bardelli Cancer discovery 4 (11), 1269-1280, 2014 | 526 | 2014 |
| Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer M Ligorio, S Sil, J Malagon-Lopez, LT Nieman, S Misale, M Di Pilato, ... Cell 178 (1), 160-175. e27, 2019 | 494 | 2019 |
| EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020 | 368 | 2020 |
| Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ... Cancer discovery 6 (1), 36-44, 2016 | 314 | 2016 |
| Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014 | 304 | 2014 |
| Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer S Arena, B Bellosillo, G Siravegna, A Martínez, I Canadas, L Lazzari, ... Clinical cancer research 21 (9), 2157-2166, 2015 | 297 | 2015 |
| KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition S Misale, JP Fatherree, E Cortez, C Li, S Bilton, D Timonina, DT Myers, ... Clinical Cancer Research 25 (2), 796-807, 2019 | 239 | 2019 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 234 | 2020 |
| KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy E Valtorta, S Misale, A Sartore‐Bianchi, ID Nagtegaal, F Paraf, ... International journal of cancer 133 (5), 1259-1265, 2013 | 228 | 2013 |
| Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants MH Hofmann, D Gerlach, S Misale, M Petronczki, N Kraut Cancer Discovery 12 (4), 924-937, 2022 | 203 | 2022 |
| Resistance to TRK inhibition mediated by convergent MAPK pathway activation E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ... Nature medicine 25 (9), 1422-1427, 2019 | 203 | 2019 |
| Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy M Di Pilato, EY Kim, BL Cadilha, JN Prüßmann, MN Nasrallah, ... Nature 570 (7759), 112-116, 2019 | 195 | 2019 |
| Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ... Journal of the National Cancer Institute 108 (1), djv306, 2016 | 153 | 2016 |
| Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers S Misale, I Bozic, J Tong, A Peraza-Penton, A Lallo, F Baldi, KH Lin, ... Nature communications 6 (1), 8305, 2015 | 139 | 2015 |
| TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells S Hobor, BO Van Emburgh, E Crowley, S Misale, F Di Nicolantonio, ... Clinical Cancer Research 20 (24), 6429-6438, 2014 | 137 | 2014 |
| MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations S Arena, G Siravegna, B Mussolin, JD Kearns, BB Wolf, S Misale, ... Science translational medicine 8 (324), 324ra14-324ra14, 2016 | 105 | 2016 |
| Anatomic position determines oncogenic specificity in melanoma JM Weiss, MV Hunter, NM Cruz, A Baggiolini, M Tagore, Y Ma, S Misale, ... Nature 604 (7905), 354-361, 2022 | 80 | 2022 |
| Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer R Yaeger, R Mezzadra, J Sinopoli, Y Bian, M Marasco, E Kaplun, Y Gao, ... Cancer discovery 13 (1), 41-55, 2023 | 69 | 2023 |
| STAT3 can serve as a hit in the process of malignant transformation of primary cells M Demaria, S Misale, C Giorgi, V Miano, A Camporeale, J Campisi, ... Cell Death & Differentiation 19 (8), 1390-1397, 2012 | 61 | 2012 |
